- Home
- AIRT vs CCEL Comparison
AIRT vs CCEL Comparison
Compare AIRT & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- CCEL
- Stock Information
- Founded
- AIRT 1980
- CCEL 1989
- Country
- AIRT United States
- CCEL United States
- Employees
- AIRT N/A
- CCEL N/A
- Industry
- AIRT Air Freight/Delivery Services
- CCEL Managed Health Care
- Sector
- AIRT Consumer Discretionary
- CCEL Health Care
- Exchange
- AIRT Nasdaq
- CCEL Nasdaq
- Market Cap
- AIRT 46.9M
- CCEL 51.9M
- IPO Year
- AIRT N/A
- CCEL 1997
- Fundamental
- Price
- AIRT $17.95
- CCEL $6.44
- Analyst Decision
- AIRT
- CCEL Strong Buy
- Analyst Count
- AIRT 0
- CCEL 1
- Target Price
- AIRT N/A
- CCEL $8.50
- AVG Volume (30 Days)
- AIRT 5.0K
- CCEL 16.7K
- Earning Date
- AIRT 02-12-2025
- CCEL 04-14-2025
- Dividend Yield
- AIRT N/A
- CCEL 3.91%
- EPS Growth
- AIRT N/A
- CCEL N/A
- EPS
- AIRT N/A
- CCEL 0.05
- Revenue
- AIRT $298,215,000.00
- CCEL $31,986,106.00
- Revenue This Year
- AIRT N/A
- CCEL $2.21
- Revenue Next Year
- AIRT N/A
- CCEL $0.98
- P/E Ratio
- AIRT N/A
- CCEL $129.41
- Revenue Growth
- AIRT 3.36
- CCEL 2.05
- 52 Week Low
- AIRT $14.85
- CCEL $5.75
- 52 Week High
- AIRT $30.60
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- AIRT 51.08
- CCEL 42.96
- Support Level
- AIRT $16.56
- CCEL $6.13
- Resistance Level
- AIRT $18.13
- CCEL $6.56
- Average True Range (ATR)
- AIRT 0.51
- CCEL 0.38
- MACD
- AIRT 0.10
- CCEL 0.04
- Stochastic Oscillator
- AIRT 43.85
- CCEL 50.89
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.